Abstract
Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baylin SB, Herman JG . 2000 Trends Genet. 16: 168–174
Borden KL . 1998 Biochem. Cell. Biol. 76: 351–358
Casini T, Pelicci PG . 1999 Oncogene 18: 3235–3243
Deininger MW, Goldman JM . 1998 Curr. Opin. Hematol. 5: 302–308
Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH . 2000 EMBO J. 19: 843–851
Ferrara F, Fazi F, Padula F, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C . 2001 Cancer Res in press
Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA . 1998 Mol. Cell. Biol. 18: 7185–7191
Glass CK, Rosenfeld MG . 2000 Genes Dev. 14: 121–141
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG . 1998 Nature 391: 815–818
Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R . 2000 Genes Dev. 14: 1048–1057
Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A . 1998 Blood 91: 2634–2642
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP . 1998 Nat. Genet. 18: 126–135
Hiebert SW, Downing JR, Lenny N, Meyers S . 1996 Curr. Top. Microbiol. Immunol. 211: 253–258
Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA . 2000 Genes Dev. 14: 45–54
Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J . 1997 EMBO J. 16: 69–82
Kastner P, Lawrence J, Waltzinger C, Ghyselinck N, Chambon P, Chan S . 2001 Blood in press
Kitabayashi I, Yokoyama A, Shimizu K, Ohki M . 1998 EMBO J. 17: 2994–3004
Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA . 1997 Science 278: 1309–1312
Lemon B, Tjian R . 2000 Genes Dev. 14: 2551–2569
Lin RJ, Evans RM . 2000 Mol. Cell 5: 821–830
Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM . 1998 Nature 391: 811–814
Liu M, Iavarone A, Freedman LP . 1996a J. Biol. Chem. 271: 31723–31728
Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP . 1996b Genes Dev. 10: 142–153
Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG . 1999 Blood 94: 12–22
Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW . 1998 Mol. Cell. Biol. 18: 7176–7184
Marks PA, Richon VM, Rifkind RA . 2000 J. Natl. Cancer Inst. 92: 1210–1216
Matsumura I, Ishikawa J, Nakajima K, Oritani K, Tomiyama Y, Miyagawa J, Kato T, Miyazaki H, Matsuzawa Y, Kanakura Y . 1997 Mol. Cell. Biol. 17: 2933–2943
Melnick A, Licht JD . 1999 Blood 93: 3167–3215
Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG . 2000 Mol. Cell 5: 811–820
Minucci S, Pelicci PG . 1999 Semin. Cell. Dev. Biol. 10: 215–225
Ng HH, Bird A . 2000 Trends Biochem. Sci. 25: 121–126
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ . 1995 Science 267: 1024–1027
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG . 2000 Nature 406: 207–210
Prowse DM, Bolgan L, Molnar A, Dotto GP . 1997 J. Biol. Chem. 272: 1308–1314
Ptashne M, Gann A . 1997 Nature 386: 569–577
Saurin AJ, Borden KL, Boddy MN, Freemont PS . 1996 Trends Biochem. Sci. 21: 208–214
Strahl BD, Allis CD . 2000 Nature 403: 41–45
Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD . 1999 Oncogene 18: 1015–1022
Val Lint C, Emiliani S, Verdin E . 1996 Gene Expr. 5: 245–253
Wang J, Saunthararajah Y, Redner RL, Liu JM . 1999 Cancer Res. 59: 2766–2769
Warrell Jr RP, He LZ, Richon V, Calleja E, Pandolfi PP . 1998 J. Natl. Cancer Inst. 90: 1621–1625
Westervelt P, Ley TJ . 1999 Blood 93: 2143–2148
Xu L, Glass CK, Rosenfeld MG . 1999 Curr. Opin. Genet. Dev. 9: 140–147
Zeng YX, el-Deiry WS . 1996 Oncogene 12: 1557–1564
Zeng YX, Somasundaram K, el-Deiry WS . 1997 Nat. Genet. 15: 78–82
Zhang J, Hug B, Huang E, Chen C, Gelmetti V, Maccarana M, Minucci S, Pelicci PG, Lazar MA . 2001 Mol. Cell. Biol. 21: 156–163
Zhong S, Salomoni P, Pandolfi PP . 2000 Nat. Cell. Biol. 2: E85–E90
Acknowledgements
We gratefully acknowledge Philippe Kastner for sharing results prior to publication, and people from our labs for useful discussions.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minucci, S., Nervi, C., Coco, F. et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 20, 3110–3115 (2001). https://doi.org/10.1038/sj.onc.1204336
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204336
Keywords
This article is cited by
-
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα
Cell Death & Differentiation (2023)
-
Three-dimensional quantitative structural-activity relationship and molecular dynamics study of multivariate substituted 4-oxyquinazoline HDAC6 inhibitors
Molecular Diversity (2023)
-
A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies
Cell Death & Disease (2021)
-
Identification of benzamide inhibitors of histone deacetylase 1 from Babesia and Theileria species via high-throughput virtual screening and molecular dynamics simulations
Parasitology Research (2021)
-
ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia
Oncogene (2014)